Novo Nordisk A/S

WBAG:NNO2 Stock Report

Market Cap: €457.6b

Novo Nordisk Management

Management criteria checks 3/4

Novo Nordisk's CEO is Lars Jorgensen, appointed in Jan 2017, has a tenure of 7.92 years. directly owns 0.002% of the company’s shares, worth €9.61M. The average tenure of the management team and the board of directors is 3.8 years and 6.8 years respectively.

Key information

Lars Jorgensen

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure7.9yrs
CEO ownership0.002%
Management average tenure3.8yrs
Board average tenure6.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Lars Jorgensen's remuneration changed compared to Novo Nordisk's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

DKK 95b

Jun 30 2024n/an/a

DKK 90b

Mar 31 2024n/an/a

DKK 89b

Dec 31 2023n/an/a

DKK 84b

Sep 30 2023n/an/a

DKK 75b

Jun 30 2023n/an/a

DKK 67b

Mar 31 2023n/an/a

DKK 61b

Dec 31 2022DKK 60mDKK 17m

DKK 56b

Sep 30 2022n/an/a

DKK 53b

Jun 30 2022n/an/a

DKK 51b

Mar 31 2022n/an/a

DKK 49b

Dec 31 2021DKK 58mDKK 17m

DKK 48b

Sep 30 2021n/an/a

DKK 46b

Jun 30 2021n/an/a

DKK 44b

Mar 31 2021n/an/a

DKK 43b

Dec 31 2020DKK 57mDKK 14m

DKK 42b

Sep 30 2020n/an/a

DKK 42b

Jun 30 2020n/an/a

DKK 41b

Mar 31 2020n/an/a

DKK 40b

Dec 31 2019DKK 55mDKK 14m

DKK 39b

Sep 30 2019n/an/a

DKK 39b

Jun 30 2019n/an/a

DKK 38b

Mar 31 2019n/an/a

DKK 38b

Dec 31 2018DKK 41mDKK 11m

DKK 39b

Sep 30 2018n/an/a

DKK 38b

Jun 30 2018n/an/a

DKK 39b

Mar 31 2018n/an/a

DKK 39b

Dec 31 2017DKK 32mDKK 9m

DKK 38b

Compensation vs Market: Insufficient data to establish whether Lars's total compensation is reasonable compared to companies of similar size in the Austrian market.

Compensation vs Earnings: Lars's compensation has been consistent with company performance over the past year.

CEO

Lars Jorgensen (58 yo)

7.9yrs

Tenure

DKK 60,100,000

Compensation

Mr. Lars Fruergaard Jorgensen serves as Director at Danmarks Nationalbank since April 2024. He has been Chief Executive Officer and President of Novo Nordisk A/S since January 2017and serves as its Member...

Leadership Team

NamePositionTenureCompensationOwnership
Lars Jorgensen
President7.9yrsDKK 60.10m0.0021%
€ 9.6m
Karsten Knudsen
Executive VP6.8yrsDKK 21.50m0.000010%
€ 45.8k
Henrik Wulff
Executive VP of Product Supplyno dataDKK 22.00m0.000060%
€ 274.6k
Camilla Sylvest
Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Boardno dataDKK 21.30mno data
Martin Lange
Executive VP of Development & Member of the Management Board3.9yrsDKK 20.90mno data
Marcus Schindler
EVP of Research & Early Development3.8yrsDKK 20.90mno data
Maziar Doustdar
Executive VP of International Operations & Member of the Management Boardno datano data0.0011%
€ 5.2m
Douglas Langa
Executive VP of North America Operations & Member of Management Boardno datano datano data
Ludovic Helfgott
Executive VPno datano datano data
Tania Sabroe
Executive VP of Global People & Organisation and Member of Management Board1.8yrsno datano data
David Moore
Executive VP of Corporate Development & Member of Management Board1.8yrsno datano data
Jacob Martin Rode
Head of Investor Relationsno datano datano data

3.8yrs

Average Tenure

54yo

Average Age

Experienced Management: NNO2's management team is considered experienced (3.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Sylvie Gregoire
Independent Director9.8yrsDKK 1.80mno data
Helge Lund
Independent Chairman of the Board7.8yrsDKK 3.10mno data
Henrik Poulsen
Vice Chairman of the Board3.8yrsDKK 2.00mno data
Laurence Debroux
Independent Director5.8yrsDKK 2.00mno data
Martin MacKay
Independent Director6.8yrsDKK 1.70mno data
Andreas Fibig
Independent Director6.8yrsDKK 1.40mno data
Kasim Kutay
Non-Independent Director7.8yrsDKK 1.20mno data
Christina Law
Independent Director2.8yrsDKK 1.30mno data
Liselotte Hyveled
Employee Representative Director2.8yrsDKK 800.00k0%
€ 0
Mette Jensen
Employee Non-Independent Representative Director6.8yrsDKK 1.20mno data
Thomas Rantzau
Employee Representative Non-Independent Director6.9yrsDKK 1.00mno data
Elisabeth Christensen
Employee Representative Director2.8yrsDKK 800.00kno data

6.8yrs

Average Tenure

58.5yo

Average Age

Experienced Board: NNO2's board of directors are considered experienced (6.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 06:58
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Novo Nordisk A/S is covered by 71 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Kamla SinghAlphaValue
Gerhard SchwarzBaader Helvea Equity Research